37th Annual Advances in Heart Disease
Results of the COMPASS and VOYAGER PAD Trials: Is Rivaroxaban in Combination with Aspirin More Effective than Aspirin Alone for Secondary Cardiovascular Prevention in Patients with PAD?
By
37th Annual Advances in Heart Disease
FEATURING
Mark Creager
By
37th Annual Advances in Heart Disease
FEATURING
Mark Creager
Comments 1
Login to view comments.
Click here to Login